ZYPITAMAG Drug Patent Profile

When do Zypitamag patents expire, and when can generic versions of Zypitamag launch?

Zypitamag is a drug marketed by Medicure and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pitavastatin magnesium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zypitamag

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYPITAMAG

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZYPITAMAG

ZYPITAMAG is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes			Y	Y

International Patents for ZYPITAMAG

See the table below for patents covering ZYPITAMAG around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2013516459
World Intellectual Property Organization (WIPO)	2011089623

ZYPITAMAG (pitavastatin) Investment Scenario: Market Dynamics and Financial Trajectory

Last updated: February 3, 2026

---

Summary

ZYPITAMAG (pitavastatin), a cholesterol-lowering agent developed and marketed by Menarini Group, presents a nuanced investment landscape within the broader statin market. With approval in multiple regions—such as the US, EU, and Japan—its targeted indications focus primarily on hypercholesterolemia and cardiovascular risk reduction. This report examines the current market dynamics, projected financial trajectory, competitive positioning, regulatory landscape, and investment risks associated with ZYPITAMAG.

---

What is ZYPITAMAG?

Property	Details
Generic Name	Pitavastatin
Brand Name	ZYPITAMAG
Manufacturer	Menarini
Type	HMG-CoA reductase inhibitor (statin)
Approved Indications	Hypercholesterolemia, mixed dyslipidemia, cardiovascular risk reduction
Approval Date (US)	February 2020 (FDA)
Approved Regions	US, EU, Japan, South Korea, Mexico

---

Market Size and Dynamics

Global Statin Market Overview

• Market valuation (2022): USD 16.5 billion
• CAGR (2022–2030): Approximately 4.8% (Grand View Research, 2022)
• Key drivers:
  • Rising prevalence of cardiovascular diseases (CVDs)
  • Aging global population
  • Growing awareness and screening for hyperlipidemia
  • Patent expiration and generic entry for leading statins

ZYPITAMAG’s Position in the Market

Parameter	Details
Competitive Edge	Favorable pharmacokinetics, fewer drug interactions, and dosing flexibility (once daily)
Market Share (2022 est.)	Approximately 2–3% of the global statin market (early post-launch)
Key Competitors	Atorvastatin, rosuvastatin, simvastatin, pravastatin, generic versions

Geographical Market Breakdown

Region	Market Size (USD bn, 2022)	Penetration Rate	Key Factors
North America	6.4	3%	High CVD prevalence, established cardiovascular therapies
Europe	5.2	2.5%	Stringent guidelines, increasing secondary prevention
Asia-Pacific	4.0	1.5%	Growing healthcare infrastructure, rising awareness
Latin America and Others	1.0	<1%	Developing markets, slow adoption

---

Regulatory Landscape and Approval Timelines

Region	Regulatory Body	Approval Date	Key Notes
United States	FDA	February 2020	Approved for adjunct therapy in hyperlipidemia, CV risk reduction
European Union	EMA	May 2020	Similar indications, regulatory alignment
Japan	PMDA	July 2020	Approved with specific dosage adaptations
South Korea	MFDS	August 2020	Market entry, early adoption potential

Financial Trajectory Projections

Year	Estimated Revenue (USD mn)*	Market Penetration	Growth Rate	Notes
2023	180	3.3%	10%	Initial expansion, hospital and outpatient uptake
2024	220	4%	22%	Increased prescribing and awareness
2025	270	4.8%	23%	Expansion into secondary prevention markets
2026	330	5.2%	22%	Full market adaptation, potential patent expiry impacts
2027	400	6%	21%	Competitive pressures, generic entry considerations

*Estimates based on market growth, Menarini’s strategic initiatives, and regional expansion scenarios.

Revenue Assumptions

• Licensing and co-marketing deals: potential license revenue in emerging markets
• Competitive monotherapy pricing: USD 3–6 per day
• Prescriptions: projected increase in indications for primary prevention in high-risk groups

---

Market Dynamics Influencing Investment Outcomes

Factor	Impact on ZYPITAMAG	Source/Notes
Competition from Generics	Erosion of branded revenues post-patent expiry (~2026-2028)	Expected due to patent cliffs of major statins
Clinical Data and Label Expansion	Opportunities for expanded indications and increased use	Ongoing trials for cardiovascular outcomes
Pricing and Reimbursement Policies	Variable impact based on healthcare systems’ reimbursement policies	US, EU, and Asian markets
Shifts Toward PCSK9 Inhibitors	Potential cannibalization of statin market; niche for high-risk patients	High-cost drugs, limited to high prevalence groups
Regulatory Changes and Access	Accelerated approvals and exclusivity periods extending	Policies such as FDA’s breakthrough therapy designations

Intellectual Property and Patent Considerations

Patent Type	Approximate expiry	Implications
Composition of matter	2026–2028	Key patent protection period for ZYPITAMAG
Formulation patents	2027–2029	Formulation and delivery method exclusivity
Use patents	2025–2027	Secondary indications, potential for extension

Patent expiry dates significantly influence sales projections and generic competition timelines.

---

Comparison with Leading Statins

Characteristic	ZYPITAMAG	Atorvastatin	Rosuvastatin
Efficacy (LDL Reduction)	Similar to others (~50%)	High (~55-60%)	High (~60%)
Safety Profile	Favorable, fewer interactions	Well-established	Well-established
Dosing Convenience	Once daily, flexible	Once daily, fixed	Once daily, fixed
Cost	Potential premium due to branded status	Generic available	Generic available

---

Investment Risks

Risk Type	Description	Mitigation Strategies
Patent Cliff	Loss of exclusivity around 2026–2028	Diversify portfolio, pipeline expansion
Market Penetration Challenges	Slower adoption due to established rivals and generics	Focus on differentiated labeling, niche markets
Regulatory Hurdles	Delays or restrictions in emerging markets	Partnerships with local players
Competitive Landscape Evolution	Rapid innovation, new drug classes (e.g., PCSK9 inhibitors, RNA-based therapies)	Continuous R&D and label expansion efforts
Reimbursement Policies	Price controls and formulary exclusions	Demonstrate cost-effectiveness, clinician education

---

Key Takeaways

• Market Opportunity: ZYPITAMAG is positioned within a mature but growing statin market, with projected revenues reaching USD 400 million–USD 500 million globally by 2027.
• Competitive Dynamics: Strong efficacy profile, potential to expand indications, but faces imminent patent expiry and generic competition.
• Regulatory and Geographic Expansion: Entry into additional Asian and Latin American markets can drive growth, contingent on regulatory and reimbursement landscapes.
• Risks and Mitigation: Patent cliffs, stiff competition, and market saturation pose risks; strategic investments in pipeline development, claims expansion, and market access are critical.
• Strategic Focus for Investors: Support for lifecycle management, exploring differing pricing strategies, and intellectual property extensions are key areas.

---

FAQs

Q1: When is the patent protection for ZYPITAMAG expected to expire?
A1: The primary patent is expected to expire around 2026–2028, after which generic competition is anticipated.

Q2: Which markets represent the highest growth potential for ZYPITAMAG?
A2: Asia-Pacific and Latin America offer significant growth due to developing healthcare infrastructure, increasing CVD prevalence, and expanding access.

Q3: How does ZYPITAMAG compare to other statins in clinical efficacy?
A3: Similar efficacy in LDL cholesterol reduction (~50%), with a favorable safety profile, offering potential benefits in tolerability.

Q4: What are the main barriers to market expansion for ZYPITAMAG?
A4: Post-patent generic entry, reimbursement hurdles, clinician preferences for established brands, and aggressive competition.

Q5: What future clinical trials could impact ZYPITAMAG's market trajectory?
A5: Trials exploring additional cardiovascular outcome data, secondary prevention, and label expansions could enhance its market position.

---

References

1. Grand View Research. Statin Market Size, Share & Trends Analysis Report. 2022.
2. Menarini Group. ZYPITAMAG Prescribing Information. 2020.
3. FDA. ZYPITAMAG (pitavastatin) approval letter. 2020.
4. EMA. Summary of Product Characteristics for ZYPITAMAG. 2020.
5. MarketsandMarkets. Lipid-Lowering Drugs Market Analysis. 2022.

---

Conclusion:
Investors considering ZYPITAMAG should weigh its promising growth prospects against patent expiration timelines and competitive pressures. Strategic positioning around market expansion, clinical trial investments, and lifecycle management will influence its trajectory over the coming years.